Výsledky vyhledávání - "R A, Zittoun"

Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA)

Autor: S, Keating, T, de Witte, S, Suciu, F, Mandelli, E, Damasio, R, Willemze, E, Morra, S, Amadori, M, Dardenne, M L, Vegna, R A, Zittoun

Publikováno v: European journal of cancer (Oxford, England : 1990). 35(10)

In the AML 8A study patients were treated with remission-induction therapy followed by one consolidation course. Patients in complete remission (CR) were randomised between autologous bone marrow transplantation (ABMT) and a second intensive consolid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::979e4a48184cd74efa636bcd772d54f0
https://pubmed.ncbi.nlm.nih.gov/10673975

Zobrazit plný text záznamu

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto

Autor: S, Keating, T, de Witte, S, Suciu, R, Willemze, M, Hayat, B, Labar, L, Resegotti, P R, Ferrini, F, Caronia, M, Dardenne, G, Solbu, M C, Petti, M L, Vegna, F, Mandelli, R A, Zittoun

Publikováno v: British journal of haematology. 102(5)

To determine whether patients with a HLA-identical sibling donor have a better outcome than patients without a donor, an analysis on the basis of intention-to-treat principles was performed within the framework of the EORTC-GIMEMA randomized phase II

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a52c707f8dc2fd7d261bc2f407b406eb
https://pubmed.ncbi.nlm.nih.gov/9753069

Zobrazit plný text záznamu

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups

Autor: S, Keating, S, Suciu, T, de Witte, F, Mandelli, R, Willemze, L, Resegotti, G, Broccia, J, Thaler, B, Labar, E, Damasio, B, Bizzi, B, Rotoli, A, Vekhoff, P, Muus, M C, Petti, M, Dardenne, G, Solbu, M L, Vegna, R A, Zittoun

Publikováno v: Bone marrow transplantation. 17(6)

The Leukemia Cooperative Groups of the EORTC and the GIMEMA conducted a prospective randomized phase III trial, in order to assess the value of autologous BMT (ABMT) vs a second intensive consolidation course (IC2), following a common intensive conso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::183416d7c542c240fe9cc786176d8c56
https://pubmed.ncbi.nlm.nih.gov/8807105

Zobrazit plný text záznamu

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups

Autor: R A, Zittoun, F, Mandelli, R, Willemze, T, de Witte, B, Labar, L, Resegotti, F, Leoni, E, Damasio, G, Visani, G, Papa

Publikováno v: The New England journal of medicine. 332(4)

Allogeneic or autologous bone marrow transplantation and intensive consolidation chemotherapy are used to treat acute myelogenous leukemia in a first complete remission.After induction treatment with daunorubicin and cytarabine, patients who had a co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0b67ea9d622318fe574b4c5e0367ec43
https://pubmed.ncbi.nlm.nih.gov/7808494

Zobrazit plný text záznamu

High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia

Autor: R A Zittoun, Y. Pommier, J. P. Marie, L. Pochat

Publikováno v: Medical and Pediatric Oncology. 10:259-261

High doses of Cytosine-arabinoside (Ara-C) (1 to 3gm/m2 every 12 hours during 48 hours) were administered monthly to 5 acute myeloid leukemia patients during complete remissions subsequent to relapses and reinduction treatment. Plasma Ara-C was measu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59680d832eb7f6911dc20e4ad79f6e01
https://doi.org/10.1002/mpo.2950100727

Zobrazit plný text záznamu

High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics

Autor: Y, Pommier, L, Pochat, J P, Marie, R A, Zittoun

Publikováno v: Cancer treatment reports. 67(4)

High-dose cytarabine (HDARA-C) at doses ranging from 1000 to 3000 mg/m2 administered as 30-min iv infusions was used in 12 patients with acute leukemia. HDARA-C toxicity was marked by nausea, vomiting, and somnolence; fever occurred in one patient. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a2f13e651245c42539d2ec7244cb97f2
https://pubmed.ncbi.nlm.nih.gov/6850654

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání